PriceTargets.com logo

Medpace - MEDP Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $491.27
  • Forecasted Upside: -15.66%
  • Number of Analysts: 15
  • Breakdown:
  • 3 Sell Ratings
  • 10 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$582.48 As of 01/30/2026 05:00 PM ET
▼ -10.59 (-1.79%)

This chart shows the closing price for MEDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medpace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDP

Analyst Price Target is $491.27
▼ -15.66% Downside Potential
This price target is based on 15 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $491.27, with a high forecast of $660.00 and a low forecast of $305.00. The average price target represents a -15.66% upside from the last price of $582.48.

This chart shows the closing price for MEDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 15 contributing investment analysts is to reduce stock in Medpace. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
8/6/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 3 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 3 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 3 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/28/2026Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
1/12/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
1/9/2026MizuhoSet Target$660.00
12/15/2025BarclaysBoost TargetUnderweight ➝ Underweight$485.00 ➝ $525.00
11/13/2025BMO Capital MarketsInitiated CoverageMarket Perform$600.00
10/31/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
10/27/2025Truist FinancialSet Target$555.00
10/27/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/24/2025TD CowenReiterated RatingSell ➝ Sell
10/24/2025Robert W. BairdSet Target$613.00
10/24/2025TD CowenBoost TargetSell ➝ Sell$356.00 ➝ $462.00
10/24/2025BarclaysBoost TargetUnderweight ➝ Underweight$425.00 ➝ $485.00
10/24/2025MizuhoBoost TargetOutperform ➝ Outperform$575.00 ➝ $655.00
10/17/2025MizuhoBoost TargetOutperform ➝ Outperform$510.00 ➝ $575.00
10/8/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
9/27/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
9/22/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
9/9/2025Jefferies Financial GroupBoost TargetHold ➝ Hold$400.00 ➝ $450.00
9/3/2025Rothschild RedbDowngradeStrong-Buy ➝ Hold
9/3/2025Rothschild & Co RedburnDowngradeBuy ➝ Neutral$342.00 ➝ $474.00
7/29/2025UBS GroupDowngradeNeutral ➝ Sell$300.00 ➝ $305.00
7/25/2025MizuhoBoost TargetOutperform ➝ Outperform$328.00 ➝ $510.00
7/23/2025TD CowenDowngradeBuy ➝ Sell
7/23/2025William BlairReiterated RatingMarket Perform
7/23/2025Truist FinancialBoost TargetHold ➝ Hold$298.00 ➝ $436.00
7/23/2025Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$270.00 ➝ $430.00
7/23/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$300.00 ➝ $450.00
7/23/2025Robert W. BairdBoost TargetNeutral ➝ Neutral$313.00 ➝ $490.00
7/23/2025TD CowenReiterated RatingHold ➝ Sell$283.00 ➝ $366.00
6/24/2025BarclaysInitiated CoverageOutperform ➝ Equal Weight$300.00
4/23/2025Truist FinancialLower TargetHold ➝ Hold$333.00 ➝ $300.00
4/23/2025Robert W. BairdLower TargetNeutral ➝ Neutral$340.00 ➝ $313.00
4/22/2025William BlairReiterated RatingOutperform ➝ Market Perform
4/14/2025TD CowenDowngradeBuy ➝ Hold$370.00 ➝ $328.00
4/10/2025Truist FinancialLower TargetHold ➝ Hold$347.00 ➝ $333.00
4/9/2025MizuhoLower TargetOutperform ➝ Outperform$400.00 ➝ $355.00
3/24/2025Leerink PartnersUpgradeHold
3/24/2025Leerink PartnersInitiated CoverageMarket Perform$330.00
1/27/2025Robert W. BairdBoost TargetNeutral ➝ Neutral$354.00 ➝ $362.00
11/25/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$349.00 ➝ $354.00
10/23/2024TD CowenLower TargetBuy ➝ Buy$413.00 ➝ $372.00
10/23/2024Robert W. BairdDowngradeOutperform ➝ Neutral$413.00 ➝ $349.00
10/22/2024William BlairReiterated RatingOutperform
10/14/2024Truist FinancialLower TargetHold ➝ Hold$415.00 ➝ $397.00
10/14/2024Redburn AtlanticInitiated CoverageBuy$404.00
9/27/2024UBS GroupDowngradeBuy ➝ Neutral$420.00 ➝ $350.00
9/25/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$415.00 ➝ $345.00
9/20/2024Robert W. BairdLower TargetOutperform ➝ Outperform$430.00 ➝ $413.00
9/11/2024William BlairReiterated RatingOutperform
8/1/2024Truist FinancialInitiated CoverageHold$415.00
7/24/2024Robert W. BairdLower TargetOutperform ➝ Outperform$469.00 ➝ $430.00
7/24/2024Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$395.00 ➝ $336.00
7/24/2024TD CowenLower TargetBuy ➝ Buy$452.00 ➝ $434.00
7/24/2024GuggenheimLower TargetBuy ➝ Buy$464.00 ➝ $432.00
7/23/2024William BlairReiterated RatingOutperform
7/8/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$456.00 ➝ $469.00
5/29/2024TD CowenInitiated CoverageBuy$452.00
5/28/2024MizuhoInitiated CoverageBuy$435.00
4/24/2024GuggenheimBoost TargetBuy ➝ Buy$453.00 ➝ $464.00
4/24/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$446.00 ➝ $454.00
4/23/2024Jefferies Financial GroupUpgradeHold ➝ Buy$340.00 ➝ $450.00
3/18/2024Deutsche Bank AktiengesellschaftInitiated CoverageHold$395.00
2/15/2024UBS GroupUpgradeNeutral ➝ Buy$282.00 ➝ $452.00
2/14/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$312.00 ➝ $408.00
1/17/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$302.00 ➝ $312.00
10/24/2023Robert W. BairdUpgradeNeutral ➝ Outperform$270.00 ➝ $289.00
9/8/2023Robert W. BairdBoost Target$240.00 ➝ $250.00
7/26/2023Robert W. BairdBoost Target$240.00 ➝ $260.00
7/26/2023UBS GroupBoost Target$215.00 ➝ $270.00
7/25/2023GuggenheimBoost TargetBuy$252.00 ➝ $273.00
5/8/202322nd Century GroupReiterated RatingUpgrade
5/8/2023GuggenheimUpgradeNeutral ➝ Buy$252.00
2/15/2023Robert W. BairdBoost TargetNeutral$226.00 ➝ $233.00
1/13/2023Robert W. BairdBoost Target$217.00 ➝ $226.00
10/27/2022UBS GroupUpgradeSell ➝ Neutral$142.00 ➝ $238.00
10/25/2022Robert W. BairdBoost TargetNeutral$145.00 ➝ $200.00
9/7/2022UBS GroupInitiated CoverageSell$142.00
5/23/2022GuggenheimInitiated CoverageNeutral
3/17/2022Robert W. BairdBoost Target$160.00 ➝ $175.00
2/16/2022Robert W. BairdLower Target$190.00 ➝ $160.00
7/27/2021Truist FinancialReiterated RatingBuy$167.90
7/27/2021Truist FinancialBoost TargetBuy$193.00 ➝ $200.00
7/20/2021Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $205.00
3/17/2021Credit Suisse GroupBoost TargetOutperform$178.00 ➝ $181.00
2/17/2021Truist FinancialBoost Target$135.00 ➝ $180.00
2/16/2021Credit Suisse GroupBoost TargetOutperform$155.00 ➝ $178.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 33 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 61 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 51 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 60 very positive mentions
  • 30 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 88 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 35 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 24 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 24 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Medpace logo
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
Read More

Today's Range

Now: $582.48
Low: $578.84
High: $595.91

50 Day Range

MA: $584.28
Low: $544.08
High: $620.59

52 Week Range

Now: $582.48
Low: $250.05
High: $628.92

Volume

224,472 shs

Average Volume

205,263 shs

Market Capitalization

$16.41 billion

P/E Ratio

40.73

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Medpace?

The following Wall Street research analysts have issued stock ratings on Medpace in the last year: Barclays PLC, BMO Capital Markets, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Leerink Partners, Mizuho, Robert W. Baird, Rothschild & Co Redburn, Rothschild Redb, TD Cowen, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for MEDP.

What is the current price target for Medpace?

0 Wall Street analysts have set twelve-month price targets for Medpace in the last year. Their average twelve-month price target is $491.27, suggesting a possible downside of 15.7%. Mizuho has the highest price target set, predicting MEDP will reach $660.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $305.00 for Medpace in the next year.
View the latest price targets for MEDP.

What is the current consensus analyst rating for Medpace?

Medpace currently has 3 sell ratings, 10 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for MEDP.

What other companies compete with Medpace?

Other companies that are similar to Medpace include Encompass Health, Elevance Health, Hims & Hers Health, IQVIA and PayPal. Learn More about companies similar to Medpace.

How do I contact Medpace's investor relations team?

Medpace's physical mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company's listed phone number is (513) 579-9911 and its investor relations email address is [email protected]. The official website for Medpace is www.medpace.com. Learn More about contacing Medpace investor relations.